This study aimed to link pharmacokinetic (PK) data from different flurbiprofen preparations for the treatment of sore throat with published data to elucidate whether early efficacy is due to the local action of flurbiprofen or a systemic effect after absorption of the swallowed drug. Three comparative bioavailability studies conducted in healthy subjects provided data from flurbiprofen 8.75 mg formulations, including spray solution, spray gel, lozenges, and granules. A parallel interstudy comparison was made of PK parameters, including partial AUCs (pAUCs), using an ANOVA model with the calculation of 90% confidence intervals (CI) for the differences between least squares (LS) means for each of the test groups versus the respective reference groups. All three studies showed bioequivalence for the respective product comparisons. The interstudy comparison showed a slower rate of absorption for granules compared to spray solution (reference) based on Tmax, Cmax, and pAUCs for 1 h and 2 h. When AUC0.25h and AUC0.5h were considered, slower rates of absorption were also seen for lozenges and spray gel. The differences correlated with the reported time of onset of action, which is faster for the spray solution (20 min) compared to lozenges (26 min) and granules (30 min). These pAUCs provide useful data that allow for the discrimination between formulations. Moreover, the pAUC values represent <5% of the total AUC, suggesting that the early onset of pain relief is a response to immediate local absorption at the site of action rather than a systemic effect.

Cadore INV Scientific Consultant Akademicka 1 10800 Prague Czech Republic

Institute of Pharmacology 1st Faculty of Medicine Charles University Albertov 4 12800 Prague Czech Republic

Reckitt Healthcare Limited 103 105 Bath Road Slough Berkshire SL1 3UH UK

SAS BORVO Consultant 18 Av de Charade 63122 Ceyrat France

Zobrazit více v PubMed

EMA Guideline on Equivalence Studies for the Demonstration of Therapeutic Equivalence for Locally Applied, Locally Acting Products in the Gastrointestinal Tract: CPMP/EWP/239/95 Rev. 1, Corr.1*. [(accessed on 27 February 2023)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting_en.pdf.

EMA Note for Guidance on the Clinical Requirements for Locally Applied, Locally Acting Products Containing Known Constituents: CPMP/EWP/239/95 Final. [(accessed on 27 February 2023)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-requirements-locally-applied-locally-acting-products-containing-known_en.pdf.

Efe T., Sagnak E., Roessler P.P., Getgood A., Patzer T., Fuchs-Winkelmann S., Peterlein C.D., Schofer M.D. Penetration of topical diclofenac sodium 4% spray gel into the synovial tissue and synovial fluid of the knee: A randomised clinical trial. Knee Surg. Sports Traumatol. Arthrosc. 2014;22:345–350. doi: 10.1007/s00167-013-2408-0. PubMed DOI

Turner R., Wevrett S.R., Edmunds S., Brown M., Kulasekaran A., Adegoke O., Farrah J. Penetration of Flurbiprofen from a Locally Applied Sore Throat Lozenge and Spray into Cadaveric Human Pharynx Tissue: A Novel ex vivo Model and Microautoradiography Method. Clin. Pharmacol. 2021;13:13–20. doi: 10.2147/CPAA.S284433. PubMed DOI PMC

Haroutiunian S., Drennan D.A., Lipman A.G. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010;11:535–549. doi: 10.1111/j.1526-4637.2010.00809.x. PubMed DOI

Rannou F., Pelletier J.-P., Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin. Arthritis Rheum. 2016;45:S18–S21. doi: 10.1016/j.semarthrit.2015.11.007. PubMed DOI

Derry S., Moore R.A., Gaskell H., McIntyre M., Wiffen P.J. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst. Rev. 2015;2015:CD007402. doi: 10.1002/14651858.CD007402.pub3. PubMed DOI PMC

Holt R.J., Taiwo T., Kent J.D. Bioequivalence of diclofenac sodium 2% and 1.5% topical solutions relative to oral diclofenac sodium in healthy volunteers. Postgrad. Med. 2015;127:581–590. doi: 10.1080/00325481.2015.1058689. PubMed DOI

Hagen M., Baker M. Skin penetration and tissue permeation after topical administration of diclofenac. Curr. Med. Res. Opin. 2017;33:1623–1634. doi: 10.1080/03007995.2017.1352497. PubMed DOI

Tugwell P.S., Wells G.A., Shainhouse J.Z. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J. Rheumatol. 2004;31:2002–2012. PubMed

Roth S.H., Fuller P. Diclofenac topical solution compared with oral diclofenac: A pooled safety analysis. J. Pain Res. 2011;4:159–167. doi: 10.2147/JPR.S20965. PubMed DOI PMC

Kai S., Kondo E., Kawaguchi Y., Kitamura N., Yasuda K. Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration. Br. J. Clin. Pharmacol. 2013;75:799–804. doi: 10.1111/j.1365-2125.2012.04394.x. PubMed DOI PMC

Turner R., Wevrett S.R., Edmunds S., Brown M.B., Atkinson R., Adegoke O., Kulasekaran A., Shea T. Determination of the Permeation and Penetration of Flurbiprofen into Cadaveric Human Pharynx Tissue. Clin. Pharmacol. 2020;12:13–20. doi: 10.2147/CPAA.S234227. PubMed DOI PMC

de Looze F., Russo M., Bloch M., Montgomery B., Shephard A., Smith G., Aspley S. Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial. Eur. J. Gen. Pract. 2016;22:111–118. doi: 10.3109/13814788.2016.1145650. PubMed DOI

Schachtel B., Aspley S., Shephard A., Shea T., Smith G., Sanner K., Savino L., Rezuke J., Schachtel E. Onset of action of a lozenge containing flurbiprofen 8.75 mg: A randomized, double-blind, placebo-controlled trial with a new method for measuring onset of analgesic activity. Pain. 2014;155:422–428. doi: 10.1016/j.pain.2013.11.001. PubMed DOI

Russo M., Bloch M., de Looze F., Morris C., Shephard A. Flurbiprofen microgranules for relief of sore throat: A randomised, double-blind trial. Br. J. Gen. Pract. 2013;63:e149-55. doi: 10.3399/bjgp13X663118. PubMed DOI PMC

EMA Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms: EMA/CHMP/EWP/280/96 Rev1. [(accessed on 27 February 2023)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf.

FDA Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application: FDA-2013-D-1464. [(accessed on 27 February 2023)]; Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug.

TH0918 Report. 2011. [(accessed on 27 February 2023)]. An Open-Label, Randomised, Single Dose, 5-Way Crossover Pilot Study to Compare the Rate and Extent of Absorption of a 8.75 mg Flurbiprofen Lozenge with Flavour and Excipient Base Variants of a 8.75 mg Flurbiprofen Spray: EudraCT/IND Number 2010-022899-32. Available online: https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2010-022899-32/1/16101.

Lee H.-I., Choi C.-I., Byeon J.-Y., Lee J.-E., Park S.-Y., Kim Y.-H., Kim S.-H., Lee Y.-J., Jang C.-G., Lee S.-Y. Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2014;971:58–63. doi: 10.1016/j.jchromb.2014.09.007. PubMed DOI

Mano N., Narui T., Nikaido A., Goto J. Separation and determination of diastereomeric flurbiprofen acyl glucuronides in human urine by LC/ESI-MS with a simple column-switching technique. DMPK. 2002;17:142–149. doi: 10.2133/dmpk.17.142. PubMed DOI

ICH Bioequivalence for Immediate-Release Solid Oral Dosage Forms M13A. [(accessed on 13 February 2023)]; Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms.

Duquesnoy C., Lacey L.F., Keene O.N., Bye A. Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Eur. J. Pharm. Sci. 1998;6:259–264. doi: 10.1016/S0928-0987(97)10023-9. PubMed DOI

Cardot J.-M., Davit B.M. In vitro-in vivo correlations: Tricks and traps. AAPS J. 2012;14:491–499. doi: 10.1208/s12248-012-9359-0. PubMed DOI PMC

de Looze F., Shephard A., Smith A.B. Locally Delivered Flurbiprofen 8.75 mg for Treatment and Prevention of Sore Throat: A Narrative Review of Clinical Studies. J. Pain Res. 2019;12:3477–3509. doi: 10.2147/JPR.S221706. PubMed DOI PMC

Farrar J.T., Portenoy R.K., Berlin J.A., Kinman J.L., Strom B.L. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287–294. doi: 10.1016/S0304-3959(00)00339-0. PubMed DOI

Klinge S.A., Sawyer G.A. Effectiveness and safety of topical versus oral nonsteroidal anti-inflammatory drugs: A comprehensive review. Physician Sportsmed. 2013;41:64–74. doi: 10.3810/psm.2013.05.2016. PubMed DOI

Ware J., Coutinho G., Smith A.B., Tselenti E., Kulasekaran A. The effects of acute sore throat and cough on health-related quality of life (HRQOL) in the 2020 US general population. Eur. Respir. J. 2021;58:PA3130. PubMed PMC

Moore R.A., Derry S., Straube S., Ireson-Paine J., Wiffen P.J. Validating speed of onset as a key component of good analgesic response in acute pain. Eur. J. Pain. 2015;19:187–192. doi: 10.1002/ejp.536. PubMed DOI PMC

Loisios-Konstantinidis I., Paraiso R.L.M., Fotaki N., McAllister M., Cristofoletti R., Dressman J. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: A PEARRL review. J Pharm Pharmacol. 2019;71:699–723. doi: 10.1111/jphp.13070. PubMed DOI

Burova N., Bychkova V., Shephard A. Improvements in throat function and qualities of sore throat from locally applied flurbiprofen 8.75 mg in spray or lozenge format: Findings from a randomized trial of patients with upper respiratory tract infection in the Russian Federation. J. Pain Res. 2018;11:1045–1055. doi: 10.2147/JPR.S149331. PubMed DOI PMC

Radkova E., Burova N., Bychkova V., DeVito R. Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: A randomized, non-inferiority trial in the Russian Federation. J. Pain Res. 2017;10:1591–1600. doi: 10.2147/JPR.S135602. PubMed DOI PMC

Li H., Mandema J., Wada R., Jayawardena S., Desjardins P., Doyle G., Kellstein D. Modeling the onset and offset of dental pain relief by ibuprofen. J. Clin. Pharmacol. 2012;52:89–101. doi: 10.1177/0091270010389470. PubMed DOI

Soares K.C.C., Chiann C., Storpirtis S. Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations. Eur. J. Pharm. Sci. 2022;171:106127. doi: 10.1016/j.ejps.2022.106127. PubMed DOI

EMA Clinical Pharmacology and Pharmacokinetics: Questions and Answers: Topic 3.3. [(accessed on 7 February 2023)]. Available online: https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers.

Role of In Vitro Tests in the Characterisation of Locally Applied, Locally Acting Drugs in the Throat: Application to Flurbiprofen